Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
Dyne Therapeutics Inc. has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters are assigned to 3 examiners and 3 art units, indicating separate examination channels for each identified action. Counsel should coordinate scientific terminology and claim objectives across the portfolio, while developing independent responses to each examination record.
AEDER, SEAN E is the busiest examiner, with 1 pending matter. The other two actions are assigned to different examiners and art units. Counsel can use a shared technical framework to improve consistency, but should not assume that a claim amendment or argument developed for one file will address the other files’ distinct issues.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HUYNH, PHUONG N | 1 | 65.8% | +53.6% |
| BERHANE, SELAM | 1 | 59.1% | +56.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18024486 | METHODS OF PREPARING PROTEIN-OLIGONUCLEOTIDE COMPLEXES | HUYNH, PHUONG N | 29d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17796418 | ANTI-TRANSFERRIN RECEPTOR (TFR) ANTIBODY AND USES THEREOF | BERHANE, SELAM | 146d overdue |
| 18024486 | METHODS OF PREPARING PROTEIN-OLIGONUCLEOTIDE COMPLEXES | HUYNH, PHUONG N | 29d |
| Art Unit | Apps |
|---|---|
| 1641 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18024486 | METHODS OF PREPARING PROTEIN-OLIGONUCLEOTIDE COMPLEXES | HUYNH, PHUONG N | 1641 | §102§112 | Final Rejection | 29d | Pending | Mar 02, 2023 |
| 17796418 | ANTI-TRANSFERRIN RECEPTOR (TFR) ANTIBODY AND USES THEREOF | BERHANE, SELAM | 1675 | §112DP | Final Rejection | 146d overdue | Pending | Jul 29, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDyne Therapeutics Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Phuong N Huynh has the most, with 1 of Dyne Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
